Our journey began when we founded Uncommon Bio, where we set out to have the greatest possible impact on human health. We believed — and still do — that programming cells is the key to solving some of the world’s toughest problems.
With Uncommon, we proved that RNA technology could accelerate the production of safe, scalable cultivated meat. While many peers shuttered, we built one of the strongest companies at the intersection of food and biotech: preparing regulatory dossiers across the US, UK, and EU; scaling production to pilot; hiring world-class talent; and raising $50M from leading investors including Sam Altman and Max Altman, Balderton, and Lowercarbon. Our products convinced even meat eaters, validating that our underlying biology worked in the real world.
In 2021, we developed a new polysaccharide-based delivery system to deliver RNAs (mRNA and saRNA) into cells — originally to overcome the cost, safety, and scalability limits of existing technologies. What we discovered was far bigger: a system that performed exceptionally well in vivo, proven safe, precise highly versatile, and capable of carrying multiple types of RNA cargo.
We subsequently sold our cultivated meat business, validating the strength of that platform and allowing us to fully focus on the far greater opportunity in medicine. That breakthrough became the foundation for SymphoRNA. Today, we are applying our polysaccharide delivery platform to medicine — unlocking programmable, multi-target RNA therapeutics designed to treat complex diseases in ways traditional approaches never could.